Animal models of cerebral amyloid angiopathy
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cerebral amyloid angiopathy (CAA), due to vascular amyloid β (Aβ) deposition, is a risk factor for intracerebral haemorrhage and dementia. CAA can occur in sporadic or rare hereditary forms, and is almost invariably associated with Alzheimer’s disease (AD). Experimental (animal) models are of great interest in studying mechanisms and potential treatments for CAA. Naturally occurring animal models of CAA exist, including cats, dogs and non-human primates, which can be used for longitudinal studies. However, due to ethical considerations and low throughput of these models, other animal models are more favourable for research. In the past two decades, a variety of transgenic mouse models expressing the human Aβ precursor protein (APP) has been developed. Many of these mouse models develop CAA in addition to senile plaques, whereas some of these models were generated specifically to study CAA. In addition, other animal models make use of a second stimulus, such as hypoperfusion or hyperhomocysteinemia (HHcy), to accelerate CAA. In this manuscript, we provide a comprehensive review of existing animal models for CAA, which can aid in understanding the pathophysiology of CAA and explore the response to potential therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“Although many studies describe only minimal development of CAA in 5xFAD mice (expressing human APP695 with the Swedish, London and Florida (I716V) mutations, as well as the M146L and L286V mutations in human PS1 under control of the mouse Thy1 promoter (150)), some CAA can be detected as early as 3 months of age using…”
BackgroundAlzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“6 PDAPP mice PDAPP mice overexpress (18-fold) human APP770 with the V717F Indiana mutation under control of the platelet-derived growth factor (PDGF)-β (120).”
BackgroundThe glymphatic system: a beginner's guide
Jessen, N. A., Munk, A. S. F., Lundgaard, I., & Nedergaard, M. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1581-6 · Cited by 2,075 · cited 1×
“It is believed that the accumulation of Aβ in the vasculature might be caused by impairment of the glymphatic system, and in turn, that accumulation of Aβ might further impair the glymphatic mechanisms (193).”
BackgroundThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Impairment of paravascular clearance pathways in the aging brain
Kress, B. T., Iliff, J. J., Xia, M., Wang, M., Wei, H. S., Zeppenfeld, D., Xie, L., Kang, H., Xu, Q., Liew, J. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24271 · Cited by 1,521 · cited 1×
“Aged mice have reduced clearance of Aβ along paravascular pathways compared to young mice (192).”
BackgroundTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507 · cited 1×
“4 APP23 APP23 mice overexpress (7-fold) human APP751 with the Swedish double mutation (K670N/M671L) under control of the neuron-specific mouse Thy-1 gene promoter (104-106).”
BackgroundSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Cited by
Vasomotion as a Driving Force for Paravascular Clearance in the Awake Mouse Brain
van Veluw, S. J., Hou, S. S., Calvo-Rodriguez, M., Arbel-Ornath, M., Snyder, A. C., Frosch, M. P., Greenberg, S. M., & Bacskai, B. J. (2020) · Neuron · doi:10.1016/j.neuron.2019.10.033 · Cited by 500
“, 1987) and in Tg mice that overproduce Aβ (Jäkel et al., 2017) are predominantly found in the walls of cortical arterioles and leptomeningeal arteries, Aβ clearance appears likely to occur alongside arteries rather than veins.”
BackgroundCerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain
Aldea, R., Weller, R. O., Wilcock, D. M., Carare, R. O., & Richardson, G. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00001 · Cited by 332
Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice
Kiani Shabestari, S., Morabito, S., Danhash, E. P., McQuade, A., Sanchez, J. R., Miyoshi, E., Chadarevian, J. P., Claes, C., Coburn, M. A., Hasselmann, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110961 · Cited by 167
“CAA is associated with increased brain hemorrhages in both humans and mice (Jäkel et al., 2017; Zhang-Nunes et al., 2006), and WGCNA analysis further implicated END dysfunction.”
Patel, A. G., Nehete, P. N., Krivoshik, S. R., Pei, X., Cho, E. L., Nehete, B. P., Ramani, M. D., Shao, Y., Williams, L. E., Wisniewski, T., et al. (2021) · Brain · doi:10.1093/brain/awab129 · Cited by 44
“An important feature of cerebral amyloid-b depositions in squirrel monkeys is their predilection for abundant CAA in addition to some parenchymal amyloid depositions.(39,42,59,85) The major complication in ongoing immunotherapeutic clinical trials is ARIA, which is linked to the presence and degree of CAA.”
BackgroundMarazuela, P., Paez-Montserrat, B., Bonaterra-Pastra, A., Solé, M., & Hernández-Guillamon, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094972 · Cited by 31
“Indeed, in vitro and in vivo studies have also demonstrated that testosterone reduces Aβ deposition in AD models [60,61].”
Background
Metadata
- Authors
- Jäkel, L., Van Nostrand, W. E., Nicoll, J. A. R., Werring, D. J., & Verbeek, M. M.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2017-09-28
- Volume
- 131
- Issue
- 19
- Pages
- 2469-2488
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2756783629
- Cited by
- 70
- References
- 64
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.